Monoclonal antibodies for diagnosis of neuronal tumours and monitoring of neurodegenerative processes
Project goals
Monoclonal antibodies against cytoskeletal proteins of neurons are used for identification of tumours or neuronal origin and represent usefull probes for monitoring of neurodegenrative diseases in body fluids (cerebrospinal fluid, serum). Aim of this project is preparation of a new panel of monoclonal antibodies against high-molecular weight MAP2 proteins, that are specific for cells and tisues of neuronal origin. Antibodies will be characterized in respect of their tissue and species spedificity, epitope expozition at different fixations and ability to interact with native MAP2 proteins. Antibodies with selected properties will be usefull for better diagnosis of tumours of neuronal origin. Panel of well-characterized antibodies will represent basis for future devolepment of a new diagnostic kits for monitoring of neurodegenerative diseases.
Keywords
monoclonal antibodiesMAP2histochemistrytumours of neuronal origindiagnosisneurodegenerative diseases
Public support
Provider
Academy of Sciences of the Czech Republic
Programme
Scheme of targeted research and development support
Call for proposals
Program podpory cíleného výzkumu a vývoje 3 (SAV02003-S)
Main participants
Ústav molekulární genetiky AV ČR, v. v. i.
Contest type
VS - Public tender
Contract ID
—
Alternative language
Project name in Czech
Monoklonální protilátky pro diagnostiku nádorů neuronálního původu a monitorování neurodegenerativních procesů
Annotation in Czech
Monoklonální protilátky proti cytoskeletálním proteinům neuronů se ve stále větší míře využívají k diagnostice nádorů a představují vhodné markery pro monitorování neurodegenerativních onemocnění v tělních tekutinách (mozkomíšní mok, sérum). Cílem tohotoprojektu je připravit panel monoklonálních protilátek proti vysokomolekulárním MAP2 proteinům, které jsou specifické pro buňky a tkáně neuronálního původu. Protilátky budou charakterizovány s ohledem na jejich druhovou a tkáňovou specifitu, expozici epitopů při různých fixacích a schopnostech reagovat s nativními MAP2 proteiny. Protilátky využitelné v klinické praxi umožní přesnější imunohistochemickou a imunocytochemickou diagnostiku nádorů neuronálního původu. Panel dobře charakterizovaných protilátek bude tvořit bázi pro budoucí vývoj souprav k monitorování neurodegenerativních onemocnění.
Scientific branches
R&D category
NV - Nonindustrial research (Applied research excluded Industrial research)
CEP classification - main branch
EA - Morphology and cytology
CEP - secondary branch
EI - Biotechnology and bionics
CEP - another secondary branch
FD - Oncology and haematology
10601 - Cell biology
10602 - Biology (theoretical, mathematical, thermal, cryobiology, biological rhythm), Evolutionary biology
20801 - Environmental biotechnology
20802 - Bioremediation, diagnostic biotechnologies (DNA chips and biosensing devices) in environmental management
20803 - Environmental biotechnology related ethics
20901 - Industrial biotechnology
20902 - Bioprocessing technologies (industrial processes relying on biological agents to drive the process) biocatalysis, fermentation
20903 - Bioproducts (products that are manufactured using biological material as feedstock) biomaterials, bioplastics, biofuels, bioderived bulk and fine chemicals, bio-derived novel materials
30204 - Oncology
30205 - Hematology
30401 - Health-related biotechnology
30402 - Technologies involving the manipulation of cells, tissues, organs or the whole organism (assisted reproduction)
30403 - Technologies involving identifying the functioning of DNA, proteins and enzymes and how they influence the onset of disease and maintenance of well-being (gene-based diagnostics and therapeutic interventions [pharmacogenomics, gene-based therapeutics])
30404 - Biomaterials (as related to medical implants, devices, sensors)
30405 - Medical biotechnology related ethics
40401 - Agricultural biotechnology and food biotechnology
40402 - GM technology (crops and livestock), livestock cloning, marker assisted selection, diagnostics (DNA chips and biosensing devices for the early/accurate detection of diseases) biomass feedstock production technologies, biopharming
40403 - Agricultural biotechnology related ethics
Completed project evaluation
Provider evaluation
U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)
Project results evaluation
New monoclonal antribodies against microtubule-associated proteins MAP2ab were prepared. Characterized antibodies can be used for diagnosis of tumors of neuronal origin. Antibodies were transferred to company EXBIO Praha.
Solution timeline
Realization period - beginning
Jan 1, 2003
Realization period - end
Jan 1, 2005
Project status
U - Finished project
Latest support payment
—
Data delivery to CEP
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data delivery code
CEP06-AV0-IB-U/01:1
Data delivery date
Jun 19, 2006
Finance
Total approved costs
2,110 thou. CZK
Public financial support
1,500 thou. CZK
Other public sources
610 thou. CZK
Non public and foreign sources
0 thou. CZK
Basic information
Recognised costs
2 110 CZK thou.
Public support
1 500 CZK thou.
71%
Provider
Academy of Sciences of the Czech Republic
CEP
EA - Morphology and cytology
Solution period
01. 01. 2003 - 01. 01. 2005